Hansa Biopharma AB (publ) (HNSA.ST) Research

Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.

Market snapshot

Symbol
HNSA.ST
Price
$32.22
Day change
+0.37%
Market cap
$2.6B
P/E ratio
-4.11x
52-week range
23.3-42.98
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 1 month

Peer companies

  • BioInvent International AB (publ) (BINV.ST)
  • Cantargia AB (publ) (CANTA.ST)
  • Diamyd Medical AB (publ) (DMYD-B.ST)
  • Egetis Therapeutics AB (publ) (EGTX.ST)
  • Humana AB (publ) (HUM.ST)
  • Implantica AG (IMP-A-SDB.ST)
  • Oncopeptides AB (publ) (ONCO.ST)
  • Saniona AB (publ) (SANION.ST)

Open Hansa Biopharma AB (publ) (HNSA.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.